CSPC Pharmaceutical Group Limited (HKG:1093)

CSPC Pharmaceutical Group Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 23, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	70,471	55,169	86,022	97,707	100,932	94,800
Market Cap Growth	-35.87%	-35.87%	-11.96%	-3.19%	6.47%	-18.19%
Enterprise Value	64,112	45,415	74,600	84,557	88,212	87,594
Last Close Price	6.14	4.78	6.92	7.51	7.56	6.97
PE Ratio	15.65	11.98	13.30	14.19	14.67	15.47
Forward PE	13.43	9.76	12.05	13.86	15.70	15.49
PS Ratio	2.28	1.79	2.48	2.79	2.95	3.20
PB Ratio	1.96	1.53	2.23	2.73	3.07	3.46
P/TBV Ratio	2.25	1.76	2.53	3.08	3.24	3.68
P/FCF Ratio	-	-	30.56	15.99	25.49	14.83
P/OCF Ratio	-	-	18.68	11.33	17.73	11.84
PEG Ratio	1.90	1.03	1.03	1.03	1.03	1.03
EV/Sales Ratio	2.08	1.47	2.15	2.42	2.58	2.96
EV/EBITDA Ratio	9.72	6.79	8.53	9.83	10.31	11.98
EV/EBIT Ratio	11.42	7.95	9.65	11.07	11.50	13.48
EV/FCF Ratio	-	-	26.50	13.83	22.27	13.70
Debt / Equity Ratio	0.02	0.02	0.02	0.02	0.00	0.01
Debt / EBITDA Ratio	0.08	0.08	0.09	0.08	0.01	0.05
Debt / FCF Ratio	-	-	0.28	0.11	0.03	0.06
Asset Turnover	0.64	0.64	0.71	0.81	0.86	0.89
Inventory Turnover	2.69	2.69	3.26	3.45	3.10	2.85
Quick Ratio	1.91	1.91	2.32	2.39	2.47	2.22
Current Ratio	2.27	2.27	2.63	2.67	2.81	2.53
Return on Equity (ROE)	12.60%	12.60%	18.22%	21.32%	22.79%	24.54%
Return on Assets (ROA)	7.40%	7.40%	9.96%	11.04%	12.05%	12.13%
Return on Capital (ROIC)	9.57%	9.57%	12.91%	14.29%	15.52%	15.86%
Return on Capital Employed (ROCE)	15.40%	15.40%	19.40%	20.60%	22.70%	23.00%
Earnings Yield	6.54%	8.35%	7.52%	7.05%	6.82%	6.46%
FCF Yield	-	-	3.27%	6.26%	3.92%	6.74%
Dividend Yield	4.23%	5.44%	4.04%	2.88%	2.47%	1.83%
Payout Ratio	-	-	46.42%	34.42%	30.16%	29.61%
Buyback Yield / Dilution	1.14%	1.14%	0.38%	0.29%	0.01%	0.00%
Total Shareholder Return	5.36%	6.58%	4.43%	3.17%	2.48%	1.83%

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.